Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 0.78 |
| ▸ | AKR1B1 | P15121 | 7/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27990090 | 0.89 | PTGDR2 (0.77) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL1384739 | 0.88 | PTGDR2 (1.00) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL1385278 | 0.88 | PTGDR2 (1.00) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL1386058 | 0.85 | PTGDR2 (0.73) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL3010803 | 0.83 | PTGDR2 (0.70) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL3001517 | 0.81 | PTGDR2 (0.68) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL13208600 | 0.81 | PTGDR2 (0.68) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL1386677 | 0.80 | PTGDR2 (0.67) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL1251032 | 0.79 | PTGDR2 (0.78) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL3557583 | 0.77 | PTGDR2 (0.59) | PTGDR2AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4791729-B2 | — | — | 2011-10-12 | — | — | JP | claimed |
| US-20100197756-A1 | Indole-3-Sulphur Derivatives | ASTRAZENECA AB (SE) | 2010-08-05 | — | — | US | claimed |
| US-7723373-B2 | Indole-3-sulphur derivatives | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | claimed |
| EP-1551802-B1 | INDOLE-3-SULPHUR DERIVATIVES | ASTRAZENECA AB (SE) | 2009-12-02 | — | — | EP | claimed |
| US-20060111426-A1 | Indole-3-sulphur derivaties | ASTRAZENECA AB (SE) | 2006-05-25 | — | — | US | claimed |
| JP-2005537265-A | — | — | 2005-12-08 | — | — | JP | claimed |
| EP-1551802-A1 | INDOLE-3-SULPHUR DERIVATIVES | AstraZeneca AB (SE) | 2005-07-13 | — | — | EP | claimed |
| WO-2004007451-A1 | INDOLE-3-SULPHUR DERIVATIVES | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | WO | claimed |
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | ATOPIX THERAPEUTICS LTD (GB) | 2014-11-06 | — | — | US | disclosed |
| CN-104114169-A | Combination of CRTH2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis | ATOPIX THERAPEUTICS LTD | 2014-10-22 | — | — | CN | disclosed |
| US-20100197756-A1 | Indole-3-Sulphur Derivatives | ASTRAZENECA AB (SE) | 2010-08-05 | — | — | US | disclosed |
| US-20100197756-A1 | Indole-3-Sulphur Derivatives | ASTRAZENECA AB (SE) | 2010-08-05 | — | — | US | disclosed |
| US-20100197756-A1 | Indole-3-Sulphur Derivatives | ASTRAZENECA AB (SE) | 2010-08-05 | — | — | US | disclosed |
| US-7723373-B2 | Indole-3-sulphur derivatives | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| US-7723373-B2 | Indole-3-sulphur derivatives | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| US-7723373-B2 | Indole-3-sulphur derivatives | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| EP-1551802-B1 | INDOLE-3-SULPHUR DERIVATIVES | ASTRAZENECA AB (SE) | 2009-12-02 | — | — | EP | disclosed |
| US-20060111426-A1 | Indole-3-sulphur derivaties | ASTRAZENECA AB (SE) | 2006-05-25 | — | — | US | disclosed |
| EP-1551802-A1 | INDOLE-3-SULPHUR DERIVATIVES | AstraZeneca AB (SE) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004007451-A1 | INDOLE-3-SULPHUR DERIVATIVES | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197756-A1 | Indole-3-Sulphur Derivatives | IDO1, IDO2, INMT | PTGDR2 525/4885AKR1B1 1827/4885CYP2C9 2054/4885 |
| US-20060111426-A1 | Indole-3-sulphur derivaties | IDO1, IDO2, INMT | PTGDR2 674/4885AKR1B1 860/4885CYP2C9 547/4885 |
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | HRH2, HRH1, HRH4 | PTGDR2 59/4885AKR1B1 3801/4885CYP2C9 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.